Mirati Therapeutics, Inc., a Delaware corporation (the ?Company?), entered into an Agreement and Plan of Merger (the ?Merger Agreement?), dated October 8, 2023, with Bristol-Myers Squibb Company, a Delaware corporation (?BMS?), and Vineyard Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of BMS (?Merger Sub?), providing for the merger of Merger Sub with and into the Company (the ?Merger?), with the Company surviving the Merger as a wholly owned subsidiary of BMS. All capitalized terms used herein and not otherwise defined have the meanings given to such terms in the Merger Agreement. In connection with the consummation of the Merger and as contemplated by the Merger Agreement, as of the Effective Time, each of the directors of the Company (Faheem Hasnain; Charles Baum, M.D., Ph.D.; Bruce Carter, Ph.D.; Julie Cherrington, Ph.D.; Aaron Davis; Carol Gallagher, Pharm.D.; Craig Johnson; Maya Martinez-Davis; and Shalini Sharp) resigned and ceased to be directors of the Company and members of any committee of the Company?s board of directors. As of the Effective Time, the directors of Merger Sub immediately prior to the Effective Time became the directors of the Surviving Corporation.

The directors of Merger Sub immediately prior to the Effective Time were Konstantina Katcheves, Sandra Ramos-Alves, and Kimberly M. Jablonski. Immediately following the Effective Time, all executive officers of the Company immediately prior to the Effective Time were removed from their respective positions as the executive officers of the Surviving Corporation. Concurrently with such officers?

removal, Sandra Ramos-Alves was appointed to serve as President and Treasurer of the Company and Kimberly M. Jablonski was appointed to serve as a Vice President and Secretary of the Company.